VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009

SAN FRANCISCO, March 31, 2009 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. , a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that an abstract on the Company's Phase 2 clinical trial of VIA-2291 has been accepted for a poster presentation at the American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2009, taking place April 29 - May 1, 2009 in Washington, D.C. The presentation will summarize results of a sub-study of patients from the Company's acute coronary syndrome (ACS) trial who received serial 64 slice multidetector computed tomography (MDCT) scans before and after six months of treatment with VIA-2291.

Given AHA's embargo policy, the company will announce the data from the MDCT sub-study concurrent with the presentation.

    The poster presentation details are as follows:
          Date / Time:   Friday, May 1, 2009 8:00 a.m. - 10:00 a.m. EDT
          Location:      Omni Shoreham Hotel, Washington, DC
          Presentation:  P555
          Title:         Evaluation of Coronary Artery Atherosclerotic Plaque
                         by Serial 64-Slice Multidetector Computed Tomography
                         in Patients with Recent Acute Coronary Syndrome
                         Treated for 6 Months with 5-Lipoxygenase Inhibitor
                         VIA-2291
          Authors:       Josephine Pressacco, Montreal Heart Institute;
                         Rebecca Taub, VIA Pharmaceuticals, Inc.; Marieve
                         Cossette, Anna Nozza, Janie Paquin, Simon Kouz, Reda
                         Ibrahim, Jean Gregoire, Phillippe L'Allier, Montreal
                         Heart Institute; Ed Chiang, Tilmann M. Brotz, VIA
                         Pharmaceuticals, Inc.; Louise Fortier, Jean-Claude
                         Tardif, Montreal Heart Institute.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: .

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

    Factors that may cause actual results to differ materially from current
    expectations include, but are not limited to:
      -- our ability to borrow additional amounts under the loan from Bay
         City Capital, which is subject to the discretion of Bay City
         Capital;
      -- our ability to obtain necessary financing in the near term,
         including amounts necessary to repay the loan from Bay City Capital
         by the September 14, 2009 maturity date (or earlier if certain
         repayment acceleration provisions are triggered);
      -- our ability to control our operating expenses;
      -- our ability to comply with covenants included in the loan from Bay
         City Capital;
      -- our failure to timely recruit and enroll patients for the FDG-PET
         clinical trial, as well as any future clinical trial;
      -- our failure to obtain sufficient data from enrolled patients that
         can be used to evaluate VIA-2291, thereby impairing the validity or
         statistical significance of our clinical trials;
      -- our ability to successfully complete our clinical trials of VIA-2291
         on expected timetables and the outcomes of such clinical trials;
      -- complexities in designing and implementing cardiovascular clinical
         trials using histological examinations, measurement of biomarkers,
         medical imaging and atherosclerotic plaque bioassays;
      -- the results of our clinical trials, including without limitation,
         with respect to the safety and efficacy of VIA-2291;
      -- if the results of the ACS and CEA studies, upon further review and
         analysis, are revised or negated by authorities or by later stage
         clinical trials;
      -- our ability to obtain necessary FDA approvals;
      -- our ability to successfully commercialize VIA-2291;
      -- our ability to obtain and protect our intellectual property related
         to our product candidates;
      -- our potential for future growth and the development of our product
         pipeline, including the THR beta agonist candidate and the other
         compounds licensed from Roche;
      -- our ability to obtain strategic opportunities to partner and
         collaborate with large biotechnology or pharmaceutical companies to
         further develop VIA-2291;
      -- our ability to form and maintain collaborative relationships to
         develop and commercialize our product candidates;
      -- general economic and business conditions; and
      -- the other risks described under Item IA "Risk Factors" in our Annual
         Report on Form 10-K for the fiscal year ended December 31, 2008 on
         file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.

CONTACT: James G. Stewart, Senior Vice President and Chief FinancialOfficer of VIA Pharmaceuticals, Inc., +1-415-283-2204

Web site: http://www.viapharmaceuticals.com/

Ticker Symbol: (NASDAQ-NMS:VIAP)

Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: March 2009

View comments

Hide
(web5)